Dexloxiglumide, formerly known as CR-2017, is a CCK1 antagonist potentially for the treatment of irritable bowel syndrome. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome, dyspepsia, constipation and pancreatitis, and has had moderate success so far although trials are still ongoing. References: Serra J, Caballero N. Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2016 Oct;17(14):1969-74. doi: 10.1080/14656566.2016.1229306. Epub 2016 Sep 8. PubMed PMID: 27590736.

纯度：≥98%

CAS：119817-90-2